Aflibercept in wet AMD: specific role and optimal use

F Semeraro,1 F Morescalchi,1 S Duse,1 F Parmeggiani,2 E Gambicorti,1 C Costagliola31Department of Medical and Surgical Specialties, Radiological Specialties and Public Health, Ophthalmology Clinic, University of Brescia, Brescia, Italy; 2Department of Ophthalmology, University of Ferrara, Ferrara, I...

Full description

Saved in:
Bibliographic Details
Main Authors: Semeraro F (Author), Morescalchi F (Author), Duse S (Author), Parmeggiani F (Author), Gambicorti E (Author), Costagliola C (Author)
Format: Book
Published: Dove Medical Press, 2013-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8f29dc36355b4b72b0c6d6df1b505d13
042 |a dc 
100 1 0 |a Semeraro F  |e author 
700 1 0 |a Morescalchi F  |e author 
700 1 0 |a Duse S  |e author 
700 1 0 |a Parmeggiani F  |e author 
700 1 0 |a Gambicorti E  |e author 
700 1 0 |a Costagliola C  |e author 
245 0 0 |a Aflibercept in wet AMD: specific role and optimal use 
260 |b Dove Medical Press,   |c 2013-08-01T00:00:00Z. 
500 |a 1177-8881 
520 |a F Semeraro,1 F Morescalchi,1 S Duse,1 F Parmeggiani,2 E Gambicorti,1 C Costagliola31Department of Medical and Surgical Specialties, Radiological Specialties and Public Health, Ophthalmology Clinic, University of Brescia, Brescia, Italy; 2Department of Ophthalmology, University of Ferrara, Ferrara, Italy; 3Department of Health Science, Ophthalmology Clinic, University of Molise, Campobasso, ItalyBackground: Vascular endothelial growth factor (VEGF) is a naturally occurring glycoprotein in the body that acts as a growth factor for endothelial cells. It regulates angiogenesis, enhances vascular permeability, and plays a major role in wet age-related macular degeneration. The consistent association between choroidal neovascularization and increased VEGF expression provides a strong reason for exploring the therapeutic potential of anti-VEGF agents in the treatment of this disorder. Blockade of VEGF activity is currently the most effective strategy for arresting choroidal angiogenesis and reducing vascular permeability, which is frequently the main cause of visual acuity deterioration. In recent years, a number of other molecules have been developed to increase the efficacy and to prolong the durability of the anti-VEGF effect. Aflibercept (EYLEA®; Regeneron Pharmaceutical Inc and Bayer), also named VEGF Trap-eye, is the most recent member of the anti-VEGF armamentarium that was approved by the US Food and Drug Administration in November 2011. Because of its high binding affinity and long duration of action, this drug is considered to be a promising clinically proven anti-VEGF agent for the treatment of wet maculopathy.Objective: This article reviews the current literature and clinical trial data regarding the efficacy and the pharmacological properties of VEGF-Trap eye and describes the possible advantages of its use over the currently used "older" anti-VEGF drugs.Methods: For this review, a search of PubMed from January 1989 to May 2013 was performed using the following terms (or combination of terms): vascular endothelial growth factors, VEGF, age-related macular degeneration, VEGF-Trap eye in wet AMD, VEGF-Trap eye in diabetic retinopathy, VEGF-Trap eye in retinal vein occlusions, aflibercept. Studies were limited to those published in English.Results and conclusion: Two Phase III clinical trials, VEGF Trap-eye Investigation of Efficacy and Safety in Wet AMD (VIEW) 1 and 2, comparing VEGF Trap-eye to ranibizumab demonstrated the noninferiority of this novel compound. The clinical equivalence of this compound against ranibizumab is maintained even when the injections are administered at 8-week intervals, which indicates the potential to reduce the risk of monthly intravitreal injections and the burden of monthly monitoring.Keywords: aflibercept, AMD, neovascularization, VEGF, VEGF inhibition, VEGF-Trap eye 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Drug Design, Development and Therapy, Vol 2013, Iss default, Pp 711-722 (2013) 
787 0 |n http://www.dovepress.com/aflibercept-in-wet-amd-specific-role-and-optimal-use-a13893 
787 0 |n https://doaj.org/toc/1177-8881 
856 4 1 |u https://doaj.org/article/8f29dc36355b4b72b0c6d6df1b505d13  |z Connect to this object online.